therapeutics-pharmaceuticals-2011-33.html
Novo Annual Report 2015
34 / 72
private
com
panies acacia pharma is focused on the development of compounds for the prevention and treatment of nausea and vomiting following surgery and chemotherapy. the lead programme is in phase 3 clinical development. www
.acaciapharma.com allakos develops
monoclonal antibody-based therapies to target eosinophils and mast cells. the lead programme is in phase 1 clinical development. www.allakos.com anaptysbio is an antibody therapeutics company and a leader in antibody discovery and optimisation. www.anaptysbio.com anokion develops novel peptide and protein therapeutics with very low immunogenicity. the company is focused on products for orphan diseases. www.anokion.com apollo endosurgery markets orbera ® and lap-band ® for the treatment of obesity. the company is a leader in flexible endoscopic surgery via overstitch tm and other endoscopic devices. www.apolloendo.com cardeas pharma is developing a treatment for pneumonia in patients in intensive care units. the lead product is in phase 2 clinical development. www.cardeaspharma.com ceterix orthopaedics develops novel surgical tools for arthroscopic procedures. this technology has applications in numerous arthroscopic procedures in knees, hips and shoulders. the product is launched in the us. www.ceterix.com cianna medical is a medical device company focused on breast surgery products. the company manufactures and markets the savi breast brachytherapy applicator and the scout surgical guidance system. www.ciannamedical.com corvus pharmaceuticals develops drugs that harness the immune system to fight cancer in a new area of medicine known as immuno-oncology. www.corvuspharma.com delenex therapeutics develops therapeutic antibody fragments designed for local/topical use. www.delenex.com e-scape bio develops a pipeline of apoe4 structure correctors for the treatment of neurodegenerative diseases, including alzheimer?s disease. encarta therapeutics plans to develop novel cell therapies for cancer. www.encartatx.com epsilon-3 bio develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. the lead compound is in pre-clinical development. galera therapeutics is a clinical-stage company focused on the development of highly selective small molecule dismutase mimetics, initially targeting the prevention of radiation- induced toxicity, including mucositis. www.galeratx.com irhythm technologies is a medical device company that develops and markets the zio ® service ? an innovative cardiac monitoring and diagnostic solution which uses a single-use wearable patch to detect cardiac arrhythmias. www.irhythmtech.com kalvista pharmaceuticals develops plasma kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema. the lead programme is in phase 2 clinical development. www.kalvista.com kanyos bio is a spin-out from anokion. the company focuses on autoimmune diseases (e.g. celiac diseases and type 1 diabetes) under an option deal with astellas. www.kanyos.com karus therapeutics develops innovative therapies for the treatment of inflammation and cancer. the lead programmes are in pre-clinical development and focus on histone deacetylase and phosphoinositide 3-kinase inhibitors. www.karustherapeutics.com e-scape bio novo ventures novo a/s 34
www-com-develops-35.html
